IgGenix revealed promising data about its primary candidate, IGNX001. This candidate is an IgG4 monoclonal antibody therapy designed to treat peanut allergy.

Finerenone significantly improved cardiovascular outcomes in adults with a prevalent form of heart failure, addressing a significant medical need.

Tolebrutinib achieves main goal in HERCULES phase 3 trial, proving to be the first to reduce disability progression in non-relapsing secondary progressive multiple sclerosis.

we will use the drug Fulzerasib as an example to demonstrate how to quickly obtain information about its chemical structure and patent situation using the Synapse database and Patsnap Chemical.

Grit Biotechnology gains U.S. FDA approval for GT201 investigational new drug application, a genetically modified TIL, after receiving Chinese IND approval.

On September 2, 2024, Arrowhead Pharmaceuticals (referred to as "Arrowhead") announced the results of the Phase 3 PALISADE study for plozasiran in patients with familial chylomicronemia syndrome (FCS).

FDA Grants Emergency Use Authorization to Novavax's Updated COVID-19 Vaccine for Ages 12 and Up.

The launch of the bispecific DLL3/CD3 antibody Tarlatamab marks a significant turning point for targeting DLL3.

Pierre Fabre Laboratories gets green light from EC for BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) combo to treat adults with advanced BRAFV600E-mutant NSCLC.

Alnylam Shares In-Depth Findings from Successful Phase 3 HELIOS-B Study of Vutrisiran in ATTR Amyloidosis Cardiomyopathy Patients at ESC Congress.

Sep 4th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Orgenesis Reports Favorable Outcomes from a Practical Study on ORG-101 CAR-T Treatment in CD19+ Acute Lymphoblastic Leukemia Patients.